The “most feared man in corporate America” has just set his sights on Bristol-Myers Squibb. And that may make some of Bristol-Myers more than a little uncomfortable this morning as they continue to push their controversial $74 billion Celgene buyout.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.Free Subscription